Skip to content

Qualitative Interview Study with Physicians Involved in Diagnosis and Management of IgA Nephropathy

Qualitative Interview Study with Physicians Involved in Diagnosis and Management of IgA Nephropathy - Qualitative Interview Study with Physicians Involved in Diagnosis and Management of IgA Nephropathy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000058612
Enrollment
10
Registered
2025-07-28
Start date
2025-07-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

None listed

Sponsors

Viatris Pharmaceuticals Japan G.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Physicians who meet the following criteria will be interviewed. 1.Nephrologists,internists (general/cardiovascular/renal/ hypertension/rheumatism/collagen disease), urologists who treat patients with IgA nephropathy 2. A physician who has treated 3 or more patients with primary IgA nephropathy (excluding dialysis patients) aged 18 years or older in the last 6 months

Exclusion criteria

Exclusion criteria: Physicians who meet the following criteria are excluded from the interview. 1.Nephrologists and internists working at university hospitals, clinics, and hospitals with fewer than 200 beds 2.Urologists working in clinics and hospitals with fewer than 200 beds

Design outcomes

Primary

MeasureTime frame
<Study items by screener questionnaire> Doctor's Background (Gender, Age, Year of Graduation) The prefecture of the medical institution where they work Number of years of experience in the current department Years of experience in treating patients with IgA nephropathy Whether or not the doctor is qualified as a designated physician for intractable diseases Specialist qualifications Average number of outpatients per day Number of patients with IgA nephropathy currently being treated Number of patients with IgA nephropathy treated so far Information sources for the treatment of IgA nephropathy <Interview Study Items> 1. Actual Diagnosis 2. Actual Conditions of Treatment 3. status of regional medical cooperation 4. Communication with Patients

Countries

Japan

Contacts

Public ContactAnri Watanabe

3H Medi Solution Inc. IS Promotion Office

research_info_or2@3h-ms.co.jp03-5953-2108

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026